55 Translocator protein expression in multiple sclerosis 1. Bonsack F, et al. TSPO: An Evolutionarily Conserved Protein with Elusive Functions. Int J Mol Sci. Jun 7 2018;19(6)doi:10.3390/ijms19061694 2. Vowinckel E, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Neuroscience Research. Oct 15 1997;50(2):345-353. doi:Doi 10.1002/(Sici)10974547(19971015)50:2<345::Aid-Jnr22>3.0.Co;2-5 3. Versijpt J, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler. Apr 2005;11(2):127-34. doi:10.1191/1352458505ms1140oa 4. Oh U, et al. Translocator protein PET imaging for glial activation in multiple sclerosis. J Neuroimmune Pharmacol. Sep 2011;6(3):354-61. doi:10.1007/ s11481-010-9243-6 5. Rissanen E, et al. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand (1) (1)C-PK11195. J Nucl Med. Jun 2014;55(6):939-44. doi:10.2967/jnumed.113.131698 6. Datta G, et al. Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. Mult Scler. Oct 2017;23(11):1469-1478. doi:10.1177/1352458516681504 7. Edison P, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: An [11C](R)PK11195PET and [11C]PIB-PET study. Neurobiol Dis. Dec 2008;32(3):412-9. doi:10.1016/j.nbd.2008.08.001 8. Yasuno F, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. Nov 15 2008;64(10):835-41. doi:10.1016/j. biopsych.2008.04.021 9. Ouchi Y, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. Feb 2005;57(2):168-75. doi:10.1002/ ana.20338 10. BanatiRB, et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen’s encephalitis. Neurology. Dec 10 1999;53(9):2199-203. doi:10.1212/wnl.53.9.2199 11. Cagnin A, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. Oct 2001;124(Pt 10):2014-27. doi:10.1093/ brain/124.10.2014 12. Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. Apr 2004;15(3):601-9. doi:10.1016/j.nbd.2003.12.012 13. Messmer K, et al. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington’s disease. Neurosci Lett. Jan 23 1998;241(1):53-6. doi:10.1016/s03043940(97)00967-1 14. Cagnin A, et al. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. Dec 2004;56(6):894-7. doi:10.1002/ana.20332 15. Banati RB, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain. Nov 2000;123 ( Pt 11)(11):2321-37. doi:10.1093/brain/123.11.2321 16. Colasanti A, et al. In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18) F-PBR111 PET. J Nucl Med. Jul 2014;55(7):1112-8. doi:10.2967/jnumed.113.135129 17. Venneti S, et al. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. Dec 2006;80(6):308-22. doi:10.1016/j. pneurobio.2006.10.002 18. Debruyne JC, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol. May 2003;10(3):257-64. doi:10.1046/ j.1468-1331.2003.00571.x 19. Gerhard A, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. Sep 9 2003;61(5):686-9. doi:10.1212/01.wnl.0000078192.95645.e6 20. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. Feb 2006;21(2):404-12. doi:10.1016/j.nbd.2005.08.002 21. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. Jan 2006;21(1):8993. doi:10.1002/mds.20668 22. Gerhard A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord. Oct 2004;19(10):1221-6. doi:10.1002/mds.20162 23. Ghadery C, et al. Microglial activation in Parkinson’s disease using [(18)F]-FEPPA. J Neuroinflammation. Jan 11 2017;14(1):8. doi:10.1186/s12974-0160778-1 24. Groom GN, et al. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease. J Nucl Med. Dec 1995;36(12):2207-10. 25. Henkel K, et al. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord. Jul 2004;19(7):817-821. doi:10.1002/mds.20040 26. Politis M, et al. Increased central microglial activation associated with peripheral cytokine References
RkJQdWJsaXNoZXIy MTk4NDMw